243 related articles for article (PubMed ID: 36624188)
21. ALK-Rearranged Epithelioid Mesenchymal Neoplasm: Expanding the Spectrum of Tyrosine Kinase-Altered Mesenchymal Tumors.
Gestrich CK; Davis JL; Biederman L; John I; Alaggio R; Giovannoni I; Arnold MA; Shenoy A; Tchakarov A; Al-Ibraheemi A
Mod Pathol; 2023 Dec; 36(12):100334. PubMed ID: 37726067
[TBL] [Abstract][Full Text] [Related]
22. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
23. ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus.
Mohammad N; Haimes JD; Mishkin S; Kudlow BA; Leong MY; Chew SH; Koay E; Whitehouse A; Cope N; Ali RH; Köbel M; Stewart CJR; McCluggage WG; Lee CH
Am J Surg Pathol; 2018 Oct; 42(10):1353-1359. PubMed ID: 30015720
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
[TBL] [Abstract][Full Text] [Related]
26. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Cha YJ; Shim HS
Oncotarget; 2017 Oct; 8(52):89465-89474. PubMed ID: 29163763
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.
Coffin CM; Hornick JL; Fletcher CD
Am J Surg Pathol; 2007 Apr; 31(4):509-20. PubMed ID: 17414097
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
30. ALK-rearranged Tumors Are Highly Enriched in the STUMP Subcategory of Uterine Tumors.
Devereaux KA; Kunder CA; Longacre TA
Am J Surg Pathol; 2019 Jan; 43(1):64-74. PubMed ID: 29794871
[TBL] [Abstract][Full Text] [Related]
31. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms.
Bowman CJ; Medeiros F; Fadare O; Sangoi AR; Horvai AE; Devine WP; McCluggage WG; Rabban JT
Int J Gynecol Pathol; 2023 Jan; 42(1):1-10. PubMed ID: 35180768
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
33. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
[TBL] [Abstract][Full Text] [Related]
34. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
36. Resistance Mechanisms to Targeted Therapies in
McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
[No Abstract] [Full Text] [Related]
37. Uterine Inflammatory Myofibroblastic Tumor Showing an Atypical ALK Signal Pattern by FISH and DES-ALK Fusion by RNA Sequencing: A Case Report.
Zarei S; Abdul-Karim FW; Chase DM; Astbury C; Policarpio-Nicolas MLC
Int J Gynecol Pathol; 2020 Mar; 39(2):152-156. PubMed ID: 30741845
[TBL] [Abstract][Full Text] [Related]
38. Uterine inflammatory myofibroblastic tumor.
Karpathiou G; Devouassoux-Shisheboran M; Stolnicu S; Chauleur C; Péoc'h M
Pathol Res Pract; 2023 Feb; 242():154335. PubMed ID: 36706588
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory myofibroblastic tumor of the uterus - case report.
Štiková Z; Ptáková N; Horáková M; Kosťun J; Ondič O
Cesk Patol; 2019; 55(4):239-243. PubMed ID: 31842556
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
